China Pharma Holdings Secures $5 Million in Direct Share Offering

Haikou-based China Pharma Holdings has finalized a registered direct offering of 2.5 million common shares, successfully raising $5 million in gross proceeds. The company, listed on the NYSE American, executed the sale at a price of $2.00 per share to bolster its general corporate reserves and working capital.

Today, 02:10· Money Talk· 925 reads

China Pharma Holdings Secures $5 Million in Direct Share Offering

The transaction, which officially closed on July 23, 2026, was facilitated by FT Global Capital, Inc. acting as the exclusive placement agent. The shares were issued under a shelf registration statement originally filed with the U.S. Securities and Exchange Commission in early 2024.

China Pharma Holdings operates as a specialty pharmaceutical firm focused on high-mortality conditions such as cardiovascular and infectious diseases. With its manufacturing hub centered in Hainan Province through its subsidiary, Hainan Helpson Medical & Biotechnology, the company maintains eight GMP-certified production lines intended to serve its broad distribution network across China.

China Pharma Holdings Secures $5 Million in Direct Share Offering

Comments (0)